Monrovia's Xencor Reports Larger Loss for Second Quarter of 2020

Monrovia's Xencor Corporation, "a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases," reported a net loss for the second quarter ended June 30, 2020 of $35 million, or 61 cents a share, compared to net loss of $16 million, or 28 cents, for the same period in 2019. It attributed the loss to "lower research collaboration revenue and higher research and development expenses in 2020." https://is.gd/PKqCfY

- Brad Haugaard